Cover Story

The Abdomen

Plus

Point-of-Care Test Devices in the ED
Redesigning Ambulatory Emergency Care with Point-of-Care Testing
*Candida Spp.* in the Respiratory Tract
Vasoactive Drugs in Sepsis

Controversies in VAP Diagnosis
Monitoring Peripheral Circulation
*Touch Creates a Healing Bond in Healthcare*
Women in Leadership in Intensive Care Medicine

Intensive Care Syndrome: Promoting Independence and Return to Employment
Burden Caused by Administrators and Managers
Interview: Prof. Gernot Marx, University Hospital Aachen
Country Focus: Brazil
Most patients with liver cirrhosis remain in a compensated stage for more than 10 years, regardless of the aetiology of the liver disease. The progression to decompensated cirrhosis is defined by the occurrence of a major complication such as ascites, variceal bleeding and/or hepatic encephalopathy. From here on most patients will not die because of a progressive, irreversible decrease in liver function, but because of a relatively sudden event that precipitates an acute deterioration in their clinical condition, a syndrome termed acute-on-chronic liver failure (ACLF). For many intensive care specialists, ACLF stands for a critically ill patient who is suffering from an intra- or extrahepatic acute insult with serious repercussions on both an existing chronic liver disease and on other organ functions. It also means that, as compared to the average intensive care unit (ICU) patient, the patient has an unusually high risk of death.

Concepts about cirrhosis have evolved significantly in recent years, and major advances have been made in defining the natural history of ACLF (for general reviews see Arroyo et al. 2016; Bernal et al. 2015; Sarin and Choudhury 2016). The syndrome is highly challenging for intensivists and poses difficult questions related to the recognition of precipitating factors, pathogenesis of extrahepatic organ failures, accurate prognosis, medical management, evaluation for urgent liver transplantation and finally the identification of those situations that may render intensive care futile. The present appraisal will focus on recent insights and their potential repercussions on the way intensivists should understand and manage patients with ACLF.

Definition and Natural History of Acute-on-Chronic Liver Failure

There is no uncontested universal definition for ACLF and the two most widely used definitions depend on the origin of the hepatologists—West versus East (Arroyo et al 2015; Sarin et al. 2014). For the purpose of this text we will use the definition of the European Association for the Study of the Liver – Chronic Liver Failure (EASL-CLIF) Consortium, because extrahepatic organ failure(s) and short-term mortality are central to the definition and therefore more closely mimic circumstances in the ICU. This naturally is not necessarily the final event in a progressive course of decompensating liver disease, but may occur at any point in time after diagnosis of cirrhotic liver disease. Short-term mortality (by definition 28-day mortality rate ≥15%) (Arroyo et al 2015).

Based on the chronic liver failure (CLIF) Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study a new grading system for severity of ACLF (grade 0 to 4) has been introduced built on a modified Sequential Organ Failure Assessment (SOFA) score (Tables 1 and 2). This new grading system is proving useful to diagnose the condition, to study the natural history of ACLF, to stratify patients in intervention trials and for prognostication (Gustot et al 2015; Silva et al. 2015; Shi et al. 2016).

In the CANONIC study the prevalence of ACLF in patients presenting to the hospital with acute decompensation of cirrhosis was 31%. Twenty-three percent had ACLF at the time of admission and another 11% developed ACLF during hospitalisation. Twenty-four percent of the patients required care in the ICU with one in three not fulfilling criteria for ACLF at the time of admission to the ICU. A similar prevalence ranging from 24 to 34% has been reported in other large studies from China, North America and Scandinavia (Li et al 2016; Baja et al. 2014a; Sargenti et al. 2015). Almost half of the patients with ACLF did not have a prior history of acute decompensation, or had developed the first decompensating event within the three months prior to the diagnosis of ACLF. This observation is relevant to the extent that ACLF is not necessarily the final event in a progressive course of decompensating liver disease, but may occur at any point in time after diagnosis of cirrhotic liver disease.

The clinical course of the condition is very dynamic. One study observed resolution of ACLF in 42.5% of patients across all grades of ACLF, 53.5% in ACLF-1, 34.6% in ACLF-2 and 16% in ACLF-3 (Table 1) (Gustot et al. 2015). In the CANONIC study the overall 28-day and 90-day mortality rates for patients with ACLF, who did not undergo liver transplantation, were 32.8% and 51.2%. Similar rates have
been reported in other studies (Li et al. 2016). These mortality rates are clearly different from those in patients with acute decompensation of liver cirrhosis but not fulfilling criteria for ACLF (1.9% and 9.3%, respectively). The most frequent cause of death in patients with ACLF was multiple organ failure without septic or non-septic failure (56%) which was the most frequent organ dysfunction. The high prevalence of kidney dysfunction or failure is highly prevalent in ACLF. Hepatic, renal, cerebral, coagulation and circulatory dysfunctions are well known, but important derangements in the function of the heart, immune system, adrenal glands and muscle have also been well documented. In ACLF patients in the CANONIC study kidney failure (56%) was the most frequent organ failure followed by liver failure (44%), coagulation (28%), cerebral (24%), circulation (17%) and lung failure with 9%. The number of failing organs correlates with increasing white cell count and C-reactive protein (CRP) levels (Jalan and Williams 2002). Two pathogenetic mechanisms seem to be important drivers of both intra- and extrahepatic organ dysfunctions: systemic inflammation and dysbiosis of the microbiome (Bernardi et al. 2014). In stable cirrhosis there is a clear correspondence between systemic inflammation and liver function (Child-Pugh classification: 3.4% in Child A, 8.1% in Child B and 30.8% in Child C patients (Cirera et al. 2001). Systemic inflammation may also be induced by ongoing necrosis of hepatocytes or damage to the extracellular matrix caused by alcohol, viral disease or any other aetiological mechanisms of cirrhosis. In this case the molecules inducing inflammation are called damage-associated molecular patterns (DAMPs). How inflammation contributes to organ dysfunction in ACLF has not yet been fully elucidated. Besides the well-described severe immune dysfunction associated with cirrhosis with increased susceptibility to infection, the following concepts are likely to be important (Verbeke et al. 2011): 1. The effects caused by immunopathology, a term that describes the potential negative impact of an excessive immune response (Iwasaki and Medzhitov 2015). Either PAMPs or DAMPs cause immunopathology that in turn may cause organ dysfunction. In this case defence mechanisms directed at controlling infection or immunopathology are insufficient. This is the likely mechanism in ACLF precipitated by acute bacterial infection or severe alcoholic hepatitis. 2. Failed tolerance, a concept that describes the incapacity to develop tolerance mechanisms to persistent infection-mediated inflammation (Medzhitov et al 2012). In this case persistent ‘low-grade’ systemic exposure to PAMPs or DAMPs may be the reason for ongoing ‘sterile’ inflammation for which no tolerance can be developed. This concept provides an array of potential new therapeutic targets aimed at increasing tolerance.

Recent evidence points to gut dysbiosis as a second important pathogenetic driver of organ dysfunction in ACLF (Bajaj et al. 2014b; Chen et al. 2015; Rai et al. 2014). Several factors contribute to altered microbiota in cirrhosis, including increased intestinal permeability, abnormal small intestinal motility, impaired antimicrobial defence, small intestinal bacterial overgrowth, decreased bile acid production and compromised enterohepatic circulation (Rai et al. 2014). In stable cirrhosis there is a clear change in diversity and composition of gut microbiota with progressive dysbiosis in the setting of decomposition. Similar changes
Table 2. ACLF Grades, Mortality and Disease Course Patterns

<table>
<thead>
<tr>
<th>ACLF grades</th>
<th>28 day mortality (%)</th>
<th>90 day mortality (%)</th>
<th>Disease Course Patterns</th>
</tr>
</thead>
<tbody>
<tr>
<td>No ACLF</td>
<td>1.9</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>ACLF grade 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACLF grade 1 is diagnosed with one of the following:</td>
<td>33</td>
<td>51</td>
<td>54% improve to ACLF-0 24% remain at ACLF-1 8.9% progress to ACLF-2 12.4% progress to ACLF-3</td>
</tr>
<tr>
<td>Single kidney failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single liver, coagulation, circulatory or lung failure that is associated with a serum creatinine level of 1.5-1.9 mg per dl and/or hepatic encephalopathy grade 1 or grade 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single brain failure with a serum creatinine level of 1.5-1.9 mg per dl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACLF grade 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACLF grade 2 is diagnosed when there are two organ failures of any combination</td>
<td>31</td>
<td>55</td>
<td>34.6% improve to ACLF-0 14% improve to ACLF-1 25.7% remain ACLF-2 25.7% progress to ACLF-3 ACLF grade 3</td>
</tr>
<tr>
<td>ACLF grade 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACLF grade 3 is diagnosed when there are three or more organ failures of any combination</td>
<td>74</td>
<td>78</td>
<td>16% improve to ACLF-0 4% improve to ACLF-1 12% improve to ACLF-2 68% remain at ACLF-3</td>
</tr>
</tbody>
</table>

Table 2. ACLF Grades, Mortality and Disease Course Patterns

have been reported in ACLF. In a recent trial a relative abundance of Pasteurellaceae was an independent predictor for mortality and, interestingly, the use of antibiotics had only moderate impact on the gut flora (Chen et al. 2015). Robust correlations were also observed between specific bacterial families and inflammatory cytokines such as interleukin-6 and TNF-alpha. A clear mechanistic link between pathogenic colonic mucosal microbiota and poor cognition has been demonstrated for hepatic encephalopathy (Rai et al. 2014; Bajaj et al. 2012). Remarkably, treatment with lactulose in patients with hepatic encephalopathy did not change faecal flora composition. It remains unclear how gut dysbiosis contributes to organ dysfunction. Current findings suggest that relative gut overgrowth of one type of bacteria or metabolites of certain bacteria species can contribute to inflammation and thereby to organ dysfunction.

Potential New Therapeutic Approaches

In specific situations early treatment of precipitating events such as alcoholic hepatitis with steroids or reactivation of hepatitis B with antivirals can reduce mortality. However, and for the most part, medical management of organ failure in ACLF remains supportive. Randomised trials with extracorporeal liver support systems aimed at blood purification did not result in survival benefits (Banares et al. 2013; Kribben et al. 2012). A recent observational study reported improved clinical outcome with plasma exchange in hepatitis B-related ACLF (Chen 2016). High hopes are placed in regenerative therapy of cirrhosis including the use of growth factors, the combination of G-CSF and erythropoietin, hepatocyte and stem cell transplantation (King et al. 2015; Kedarisetty et al. 2015, Shiota and Itaba 2016; Duan et al. 2013; Garg et al. 2012; Zekri et al. 2015). Granulocyte-colony stimulating factor (G-CSF) therapy in ACLF reduced organ dysfunction and improved survival (Chavez-Tapia et al. 2015). It is unclear if the positive results obtained in randomised trials with administration of G-CSF in ACLF patients will be applicable in more severe forms of ACLF in the ICU (Duan et al. 2013; Garg et al. 2012).

Prognosis, Futility and Eligibility for Liver Transplantation

Many intensivists take a reserved attitude towards the admission of ACLF patients because of the dim prognosis of the syndrome. However, several new facts have emerged in recent years that defend a change in attitude and justify a full evaluation for transplant for every patient with ACLF admitted to the ICU. First, new data show that liver fibrosis and even cirrhosis are potentially reversible if the underlying cause is removed, with significant improvement in long-term survival (Ramachandran 2015). Second, the outcome of ACLF in the ICU has improved considerably. In expert ICUs survival of patients with cirrhosis and organ failure improved from 40% in the year 2000 to 63% in the year 2010 (McPhail et al. 2014). Similarly, ICU mortality of cirrhotic patients with septic shock has decreased from 74% in 1998 to 65.5% in 2010 (Galbois et al. 2014). Third, the course of the disease is very dynamic with resolution or improvement of ACLF in 4.2% of patients. Eighty-one precent reach their final ACLF grade at one week after admission, and it is now clear that for most patients prognostication will be considerably more accurate if done towards the end of the first week of ICU stay (Gustot et al. 2015). Fourth, prognostication for these patients has improved. New scoring systems, such as the Chronic Liver Failure Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLF) score that incorporates a modified SOFA-score (CLIF-Organ Failure [OF] score), age and white blood cell count can be calculated on a daily base in order to monitor evolution/resolution of ACLF and provide a significantly better estimate of risk for mortality than the model for end-stage liver disease (MELD) or Child-Pugh score (Jalan et al. 2014).
Considering the above, indiscriminate refusal of ICU admission of ACLF patients is not acceptable any more, since no specific group of patients can be identified at the time of diagnosis for which medical ICU treatment may be considered futile. However, intensivists also need to acknowledge that patients with four or more organ failures or a CLIF-C ACLF score > 64 after one week of ICU care have 28-day mortality rates in the range of 90 to 100%. If ineligible for transplantation withdrawal of care is a reasonable option for these patients.

Liver transplantation in ACLF is controversial and fraught with uncertainties regarding case selection and timing (Pamecha et al. 2015; Reddy et al. 2015). Only 15-25 % of patients are actually transplanted (Gustot et al. 2015, Finkenstedt et al. 2013). Recent series have reported encouraging results with 1- and 5-year survival of 80-90% (Finkenstedt et al. 2013; Chan et al. 2009). Even patients with ACLF-3 may expect a 1-year survival probability of 78% (Gustot et al. 2015).

Summary

Major progress has been made in defining the natural history and prognosis of ACLF. Regenerative therapies and liver transplantation in selected cases hold promise for the future.

Conflict of Interest

Philippe Meersseman and Alexander Wilmer declare that they have no conflict of interest.

References


For full references, please email editorial@icu-management.org, visit icu-management.org or use the article QR code.

Reduce
Antibiotics

Antibiotic overuse contributes to increasing antimicrobial resistance, increased risk of drug-related adverse events and higher medical costs. Antibiotic guidance with B·R·A·H·M·S PCT™ limits antibiotic prescription to patients with true bacterial infection, allows to tailor the duration of antibiotic therapy for individual patients, and reduces significantly the antibiotic exposure with no adverse impact on patient outcome.

B·R·A·H·M·S PCT assays

Visit us at EuSEM, Vienna, booth n° 42

AB days without Procalcitonin

-23% AB days in Sepsis

-35% AB days in LRTI


© 2016 Thermo Fisher Scientific Inc. All rights reserved. B·R·A·H·M·S PCT™ and all other trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Thermo Fisher Scientific products are distributed worldwide; not all intended uses and applications mentioned in this printing are registered in every country.